P/0279/2017

  • Email
  • Help

Overview

Product details for Revlimid
Invented nameRevlimid
Active substance

Lenalidomide

Decision numberEMEA-000371-PIP04-16
PIP numberP/0279/2017
Pharmaceutical form(s)Capsule, hard
Condition(s)/indication(s)

Treatment of mature B-cell neoplasms

Route(s) of administrationOral use
PIP applicant

Celgene Europe Limited
Tel. +41 327298500
E-mail: medinfo.intl@celgene.com

Decision typeW: decision granting a waiver in all age groups for all conditions/indications

Decision